CURA_1170x120_8-22-19

Heritage Pharmaceuticals tabs Scott Delaney as president

Print Friendly, PDF & Email
EATONTOWN, N.J. — Scott Delaney is slated to join Heritage Pharmaceuticals Inc. as president.

Heritage said Tuesday that Delaney will start in the president’s role on March 1. He comes to the company from Edenbridge Pharmaceuticals, where he served as chief commercial officer.

Scott Delaney_Heritage Pharmaceuticals

Scott Delaney

At Heritage, Delaney will oversee the development and execution of commercial strategy, including all activities related to sales, marketing, commercial operations and customer service, the company said. He will report to interim chief executive officer Fakrul Sayeed.

Heritage noted that Delaney joins Sayeed and Marvin Samson, who was named chairman in August, as part of a new leadership team at the pharmaceutical company.

Delaney brings 24 years of experience in the generic and branded drug sectors to Heritage industries. Before his position as chief commercial officer at Edenbridge, he served as president and CEO for six years at Jubilant Cadista Pharmaceuticals Inc. He also previously held leadership positions at URL Pharma, Teva Pharmaceuticals USA, H-E-B, Ortho Biotech (a Johnson & Johnson company) and Eli Lilly & Co.

Heritage develops, manufactures and markets generic and legacy branded pharmaceuticals for the U.S. prescription drug market. Its portfolio encompasses more than 150 products, including such therapeutic categories as oncology, cardiovascular, metabolic disease, anti-infective and pain management, among others.

CMP_728x90

CURA_728x90_8-22-19

Comments are closed.